Summary.-The effect of 5-fluorouracil (5-FU) on the growth and cellular proliferation of hepatoma 3924A was studied using the following parameters as indices of tumour response: (1) volume measurements, (2) cell kinetic analysis including estimates of both growth and cell loss fractions, (3) changes in tumour histology and (4) tumour DNA content and DNA synthesis. Of a series of single intraperitoneally injected doses (25-300 mg/kg body weight), 150 mg/kg interrupted tumour growth most effectively with minimal toxicity within 168 h, and after 10 days treated tumour volumes were only 42% of untreated tumour size. Doses of 25 mg/kg failed to change the rate of growth while 300 mg/kg exceeded the LD50.
tumour volumes were only 42% of untreated tumour size. Doses of 25 mg/kg failed to change the rate of growth while 300 mg/kg exceeded the LD50.
Alterations of both tumour cell proliferation and histology developed well in advance of changes observed in growth. A dose of 150 mg/kg body weight blocked the transition of cells from G1 through S for a 24 h interval when cell kinetics were measured by 3H-TdR autoradiography. However, 3H-UdR incorporation into DNA following 5-FU suggested that cellular recovery from the drug was delayed for an additional 24 h. Concurrently, significant losses of tumour tissue and tumoiir DNA occurred during the first 48 h with an expected increase in both necrotic add connective tissue. During the subsequent 120 h both tumour and necrotic tissue had returned to non-treated levels, while kinetic analysis revealed (a) a slight reduction in the cell cycle time and growth fraction and (b) an increased cell loss factor. The observations from this tumour model system suggest that before using tumour volume or weight as an index of therapeutic response, the relationship between the kinetics of tumour cellularity and tumour volume must be defined.
5-FLUOROURACIL (5-FU) has been evaluated as a chemotherapeutic agent (Carter, 1970;  Greenwald, 1967; Harrap, 1973) and many aspects of both the cellular and molecular pharmacology have been studied in vitro (Adams, Breed and Valenti, 1967; Kent and Heidelberger, 1972; Bruce, 1967, 1968; Rich et al., 1958) as well as in vivo (Chadwick and Rogers, 1972; Skipper, 1971; Vietti, Eggerding and Valeriote, 1971; Wolberg, 1972) . However, a comprehensive study of the effects of 5-FU on the growth and cellular kinetics of both normal host and target tissue has not been reported.
Like many of the anti-neoplastic agents in clinical use, 5-FU exerts its main effects on rapidly dividing cells. The conversion of 5-FU to 5-fluorodeoxyuridylic acid blocks the synthesis of dTMP from dUMP and thus inhibits DNA svnthesis (Birnie, Kroeger and Heidelberger, 1963; Bosch, Harbers and Heidelberger, 1958 DNA was extracted by an adaptation (Hopkins, Flora and Schmidt, 1972) of the procedures of Schmidt and Thannhauser (1945) and of Schneider (1945) . DNA was measured in the trichloroacetic acid extracts by the method of Burton (1956) , but H2SO4 was omitted, diphenylamine was increased to 2 g/100 ml and HC104 was present at a final concentration of 0 4 mol/l. Highly polymerized DNA (Sigma Chemical Co., St Louis, Mo.) was the standard. Radioactivity in the DNA extracts was measured in " cocktails " described by Patterson and Green (1965) Estimates of the growth fraction in tumours were made by determining the ratio of the experimentally determined 1 h labelling index (LIeXp) to the theoretical 1 h labelling index (Lltheor).
where A is the constant of proportionality (Steel, 1968) and T, and Tc are the duration of the S phase and cell cycle respectively.
The potential doubling time (T) as defined by Steel (1968) Chalkley (1943) and the data expressed as the relative percentage of total tissue scored.
RESULTS

Tumour growth
The growth rate of hepatoma 3924A decreases with increasing tumour volume (Fig. 1) . For tumour volumes of less than 1000 mm3 the volume doubling time (Td) was about 2-5 days. After the mean tumour volume exceeded 1000 mm3 (Day 15), Td increased to about 4 0 days. This differs from a previous report (Looney et al., 1973) where the growth data for a number of hepatomata including 3924A were approximated by a single exponential function. This method gave a Td of 4-35 days.
In preliminary experiments a series of single doses of 5-FU were administered, ranging from 25 to 300 mg/kg body weight: 25 mg/kg had little effect on tumour growth whereas a dose of 300 mg/kg resulted in severe toxicity and exceeded the LD50 (30 days). A dose of 150 mg/kg was optimal for reducing tumour growth while maintaining toxicity at a minimum and this dose was used in the present work. The mean tumour volume was 230 ± 40 mm3 when 5-FU at 150 mg/kg was administered. At 48 h after treatment the tumour volumes were 78% of those of non-treated animals and at 10 days were only 42% of those of non-treated animals (Fig. 1) connective aild 500 blood.
Tissue composition was analysed following treatment with 150 mg/kg 5-FU (Fig. 3) (Fig. 4) .
This relationship amounts to a concentration of 7-0 mg DNA/g tissue. In tumours of similar size the amount of tumour tissue relative lished). DNA concentration, therefore, was used in conjunction with histological observations to estimate tumour cellularity.
Within 48 h after treatment with 150 mg/kg 5-FU, there was a gradual decrease in DNA concentration of the drug treated tutnours (Fig. 5) . By 7-8 days after treatment, DNA concentration reached a nadir and gradual restoration to the DNA concentration observed for non-treated tumours occurred over the contributed to the changes in DNA concentration. Since protein/g tumour was not affected by treatment with 5-FU, however, changes in water content cain be ruled out as responsible for the decrease in DNA concentration.
5-FU rapidly depressed the incorporation of 3H-deoxyuridine into tumour DNA (Fig. 6) . Minimal incorporation occurred up to 36 h following 5-FU injection (4% of non-treated value).
After 48 h, DNA synthesis recovered with enhanced incorporation relative to nontreated tumours on Days 8-14.
Cell proliferation
Per cent labelled mitoses (PLM) curves were constructed for tumours treated 7 days previously with 150 mg/kg body weight of 5-FU. At this time, growth rate, labelling index and relative tissue composition had either re-established control levels or at least stabilized ( Fig.  1, 2, 3) . The PLM data for 5-FU treated and non-treated groups of tumours were analysed by the computer method described by Simon, Stroot and Weiss (1972) (Fig. 7) . These changes, however, are not of significant magnitude to affect the growth rate of these tumours. The growth fraction of non-treated tumours was 66-5 (Table II) . For treated tumours, 150 mg/kg reduced the growth fraction to 60-8. Cell loss for tumours treated with 150 mg/kg 5-FU was calculated to be 0-56 compared with 0-61 for the non-treated tumours (Table   II) .
DISCUSSION
The growth of solid tumours, as we know it, is a function of (a) the fraction of proliferating cells, (b) the rate of cell loss and (c) the amount and type of cellular material present in the tumour (see Lala, 1971 , for review). The results presented here are from studies designed to relate quantitatively the effects of 5-FU at a cellular level with the observed retardation of tumour growth. Methods available for growth fraction (Mendelsohn, 1962; Steel, Adams and Barrett, 1966) and cell loss (Steel, 1968) determinations by 3H-thymidine incorporation do not account for wide fluctuations resulting from residual synchrony from the pulse label and from the transition of growing to non-growing cells. Perturbations in cellular proliferation and cell killing resulting from cycle-specific drugs such as 5-FU would only magnify the fluctuations in both these parameters. For this reason cell kinetic parameters were studied 7 days post-treatment, when the growth of treated tumours had stabilized.
Immediately following 5-FU injection, cells were prevented from either initiating or completing DNA replication and the S phase and G1/S phase compartments expanded for a 24 h interval (Fig. 2) . Simultaneously, the 3H-deoxyuridine incorporation into DNA was depressed (Fig. 6) Rueckert and Mueller, 1960) , providing misleading data on cell viability and proliferation status.
The reciprocating levels of necrotic and viable tumour tissue reflect a killing of cells with cell death reaching a maximum at 48 h following treatment. From our data, it appears that the removal of necrotic cells from 3924A is a slow process requiring 7 days (168 h) to reach pretreatment levels (Fig. 3) . Over the same period, the loss in DNA content reflects the removal of cells from the tissue. However, DNA content does not return to pretreatment levels until Day 21 (Fig. 5) . This discrepancy between kinetic histological and biochemical estimates of cellular response to 5-FU may be explained by a decrease in viable cell density within the tumour tissue. Dethlefsen and Riley (1973) have suggested that in drug treated tumours, the normal movement of cells from one fraction to another (e.g., proliferating to degenerating) is shifted in favour of repopulation until pretreatment conditions are restored. If this shift occurs in 3924A, then the decrease in necrotic tissue observed after 48 h could result from both a dilution with new viable cells as well as the normal removal of necrotic tissue. However, the loss of DNA from treated tumours (Fig. 5) corresponds well with the time course of necrotic tissue removal, suggesting that removal of dead cells from 3924A arises early after treatment and continues until Day 7-8 post treatment. Furthermore, the earliest that repopulation could be initiated would be after Day 4 when the 3H-UdR incorporation begins to increase. Denekamp and Thomlinson (1971) , Denekamp (1972) postulate that during the period of radiation induced mitotic delay, the cell loss occurring normally in tumours is unmasked and the tumour volume response is a function of the cell loss factor of the individual tumours. Unfortunately, application of Denekamp's postulate could not be made for 5-FU treated 3924A hepatomata since mitotic delay was not demonstrable. The mitotic frequency following 5-FU, while decreasing from 045 to 0 09 24 h post treatment, returned to normal without a rapid rise normally associated with mitotic delay (Kovacs, unpublished observation). The possibility exists, however, that even during the period of mitotic depression cell loss occurs normally, resulting in the loss and removal of tumour cells with few replacement cells.
From Table II (Wilcox, 1966) and in several experimental solid tumours (Wilcox et al., 1965) 
